Phenylethynyl-thiophene compounds for treating degenerative disorders
Summary
The USPTO granted patent US12589090B2 to Aquilus Pharmaceuticals, Inc. covering phenylethynyl-thiophene compounds that inhibit caspase 3 for treating degenerative disorders including ALS, Huntington's disease, epilepsy, multiple sclerosis, Parkinson's disease, and Alzheimer's disease. The patent claims 2 compounds and methods for their use.
What changed
The USPTO granted patent US12589090B2 on March 31, 2026, covering a class of phenylethynyl-thiophene compounds designed to inhibit and/or attenuate apoptosis via caspase 3. The patent lists Irving Sucholeiki as inventor and Aquilus Pharmaceuticals, Inc. as assignee. The compounds are directed toward treating degenerative disorders including amyotrophic lateral sclerosis, Huntington's disease, epilepsy, spinal cord injury, diabetes complications, multiple sclerosis, muscular dystrophy, Parkinson's disease, irritable bowel syndrome, and Alzheimer's disease.
Pharmaceutical companies and drug developers researching caspase inhibitors or treatments for the specified degenerative disorders should review this patent for potential freedom-to-operate concerns or licensing opportunities. The patent has no compliance deadlines or regulatory requirements; it represents an intellectual property grant rather than a regulatory obligation.
What to do next
- Review patent claims for freedom-to-operate implications if developing caspase inhibitors or therapies for specified degenerative disorders
- Consider potential licensing opportunities with Aquilus Pharmaceuticals if the technology is relevant to your pipeline
Archived snapshot
Mar 31, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Compounds and methods for the treatment of degenerative disorders
Grant US12589090B2 Kind: B2 Mar 31, 2026
Assignee
Aquilus Pharmaceuticals, Inc.
Inventors
Irving Sucholeiki
Abstract
The present disclosure relates generally to alkyne containing pharmaceutical agents, and in particular, to phenylethynyl-thiophene based compounds. More particularly, the present disclosure provides a class of compounds that can inhibit and/or attenuate apoptosis via caspase 3 for the treatment of various degenerative disorders. Additionally, the present disclosure relates to methods for treating specific degenerative disorders such as amyotrophic lateral sclerosis (ALS), Huntington's disease, epilepsy, spinal cord injury, complication due to diabetes, multiple sclerosis (MS), muscular dystrophy (MD), Parkinson's disease (PD), irritable bowel syndrome (IBS) and Alzheimer's disease (AD) in a patient comprising administering to the patient an effective amount of a present compound.
CPC Classifications
A61K 31/381 A61K 31/404 A61K 31/4436 A61P 25/28 C07D 409/12
Filing Date
2020-01-21
Application No.
17310044
Claims
2
Named provisions
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.